Skip to content

Study · Randomized controlled trial · n = 26 · 2019

6 results

Carnosine supplementation reduces plasma soluble transferrin receptor in healthy overweight or obese individuals: a pilot randomised trial.

Baye E, Ukropec J, de Courten MPJ, Kurdiova T, Krumpolec P, Fernández-Real JM, Aldini G, Ukropcova B, de Courten B

Amino acids22 Aug 2018Cited by 14 (Europe PMC)

PMID30136029 (opens in a new tab)DOI10.1007/s00726-018-2623-6 (opens in a new tab)PepBankPUB-30136029
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy overweight or obese adults, carnosine decreased plasma soluble transferrin receptor versus placebo.

    In plain wordsIn healthy overweight or obese adults, carnosine decreased plasma soluble transferrin receptor versus placebo.

    Peptide
    L-carnosine
    Outcome
    DecreaseSoluble transferrin receptor
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Blood biochemical markers · Whole body
    Studied dose
    1 g twice daily · 12 weeksAs given in this study (human).

    Measurements

    mean change difference in plasma soluble transferrin receptor
    −0.07 mg/l
    carnosine versus placebo, SE 0.03

    Source sentences

    Summary
    Carnosine supplementation decreased plasma soluble transferrin receptor compared to placebo (mean change difference ± standard error: - 0.07 ± 0.03 mg/l, p = 0.04).
    1 context sentence
    Summary · context
    We included 26 participants, who were randomly allocated to receive 1 g carnosine (n = 14) or identical placebo (n = 12) twice daily for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy overweight or obese adults, iron did not differ between carnosine and placebo.

    In plain wordsIn healthy overweight or obese adults, iron did not differ between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeIron
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Blood biochemical markers · Whole body
    Studied dose
    1 g twice daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    None of the other iron parameters were different between carnosine and placebo groups.
    2 context sentences
    Summary · context
    Iron parameters including iron, ferritin, transferrin, soluble transferrin receptor, total iron binding capacity and iron saturation were measured in serum or plasma by standard commercial assays.
    Summary · context
    We included 26 participants, who were randomly allocated to receive 1 g carnosine (n = 14) or identical placebo (n = 12) twice daily for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy overweight or obese adults, ferritin did not differ between carnosine and placebo.

    In plain wordsIn healthy overweight or obese adults, ferritin did not differ between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeFerritin
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Blood biochemical markers · Whole body
    Studied dose
    1 g twice daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    None of the other iron parameters were different between carnosine and placebo groups.
    2 context sentences
    Summary · context
    Iron parameters including iron, ferritin, transferrin, soluble transferrin receptor, total iron binding capacity and iron saturation were measured in serum or plasma by standard commercial assays.
    Summary · context
    We included 26 participants, who were randomly allocated to receive 1 g carnosine (n = 14) or identical placebo (n = 12) twice daily for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy overweight or obese adults, transferrin did not differ between carnosine and placebo.

    In plain wordsIn healthy overweight or obese adults, transferrin did not differ between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeTransferrin
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Blood biochemical markers · Whole body
    Studied dose
    1 g twice daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    None of the other iron parameters were different between carnosine and placebo groups.
    2 context sentences
    Summary · context
    Iron parameters including iron, ferritin, transferrin, soluble transferrin receptor, total iron binding capacity and iron saturation were measured in serum or plasma by standard commercial assays.
    Summary · context
    We included 26 participants, who were randomly allocated to receive 1 g carnosine (n = 14) or identical placebo (n = 12) twice daily for 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy overweight or obese adults, total iron binding capacity did not differ between carnosine and placebo.

    In plain wordsIn healthy overweight or obese adults, total iron binding capacity did not differ between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeTotal iron binding capacity
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Blood biochemical markers · Whole body
    Studied dose
    1 g twice daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    None of the other iron parameters were different between carnosine and placebo groups.
    2 context sentences
    Summary · context
    Iron parameters including iron, ferritin, transferrin, soluble transferrin receptor, total iron binding capacity and iron saturation were measured in serum or plasma by standard commercial assays.
    Summary · context
    We included 26 participants, who were randomly allocated to receive 1 g carnosine (n = 14) or identical placebo (n = 12) twice daily for 12 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy overweight or obese adults, iron saturation did not differ between carnosine and placebo.

    In plain wordsIn healthy overweight or obese adults, iron saturation did not differ between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeIron saturation
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Blood biochemical markers · Whole body
    Studied dose
    1 g twice daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    None of the other iron parameters were different between carnosine and placebo groups.
    2 context sentences
    Summary · context
    Iron parameters including iron, ferritin, transferrin, soluble transferrin receptor, total iron binding capacity and iron saturation were measured in serum or plasma by standard commercial assays.
    Summary · context
    We included 26 participants, who were randomly allocated to receive 1 g carnosine (n = 14) or identical placebo (n = 12) twice daily for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.